Sannuo Biotech (300298): Profit-side core affected by credit impairment of subsidiaries, steady growth of core products
Sannuo Biotech (300298): Continued release of CGM products to achieve profits for overseas subsidiaries
Sannuo Biotech (300298): Overseas progress continues to break through, and business continues to improve
Sannuo Biotech (300298): 2024H1 blood sugar business continues to increase gross margin and increase profitability
Sannuo Biotech (300298): Performance is in line with expectations. CGM sales and R&D are expected to advance
Sannuo Biotech (300298): Steady growth in blood sugar products, improvement in overseas business profits
Sannuo Biotech (300298): Domestic blood sugar monitoring leader second curve CGM accelerates implementation at home and abroad
Sannuo Biotech (300298): CGM opens a new growth curve, and domestic blood sugar monitoring leaders are sprouting
Sannuo Biology (300298): CGM has great potential
Sannuo Biotech (300298): Quarterly profit slightly exceeded expectations and is optimistic about CGM's continued volume
Sannuo Biotech (300298): Increased R&D investment, CGM accelerates global market expansion
Sannuo Biotech (300298): The profit side declined slightly year-on-year for the whole year, and CGM is expected to start a second growth curve
Sannuo Biotech (300298): Core business performance is in line with expectations, optimistic that CGM will start global expansion
Sannuo Biotech (300298): The performance is in line with expectations, the second-generation CGM declared for listing
Sannuo Biotech (300298) 2023 Report & 2024 Quarterly Report Review: Overseas Subsidiaries' Impairment Affects Apparent Performance, Optimistic CGM Continues to Expand
Huaan Securities released a research report on April 28 stating that it gave Sannuo Biotech (300298.SZ) a purchase rating. The main reasons for the rating include: 1) In the first quarter of 2024, the company achieved revenue of 1,014 million yuan (yoy +1
Sannuo Biotech (300298) Comment: Dragged down by overseas subsidiaries in 2023 2024Q1 exceeded expectations
Sannuo Biotech (300298): The subsidiary also showed fluctuations in performance and is optimistic about the volume of CGM products
Sannuo Biotech (300298): Rapid profit growth in 1Q24 is optimistic about full-year performance
Sannuo Biotech (300298) Company Comment: Blood sugar monitoring, steady growth, new product expansion achieved results:
No Data
No Data